2-[4-[[1-(Fluoromethyl)cyclobutyl]carbamoyl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-[4-[[1-(Fluoromethyl)cyclobutyl]carbamoyl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylic acid
• 英文别名: 2-[4-[[1-(fluoromethyl)cyclobutyl]carbamoyl]piperidin-1-yl]-6-azaspiro[3.4]octane-6-carboxylic acid
• 化学式: C₁₉H₃₀FN₃O₃
• 分子量: 367.5
• InChiKey: MITCEGPMBVEMNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  72.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• [EN] BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS<br/>[FR] COMPOSÉS AZA BICYCLIQUES UTILISÉS COMME AGONISTES DU RÉCEPTEUR MUSCARINIQUE M1
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2014045031A1

  公开（公告）日：2014-03-27

  This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R1-R5, X1, X2 and p are as defined herein.

  这项发明涉及一种激动母胆碱M1受体的化合物（化学式（1）），该化合物在治疗母胆碱M1受体介导的疾病中有用。还提供了含有这些化合物的药物组合物以及这些化合物的治疗用途。所提供的化合物的化学式中，R1-R5、X1、X2和p的定义如本文所述。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：US20160128996A1

  公开（公告）日：2016-05-12

  This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R 1 -R 5 , X 1 , X 2 and p are as defined herein.

  本发明涉及化合物（公式（1）），其是肌肉型M1受体激动剂，并且在治疗肌肉型M1受体介导的疾病方面有用。本发明还提供了含有该化合物的药物组合物以及该化合物的治疗用途。所提供的化合物的公式为R1-R5、X1、X2和p的定义如本文所述。
• BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR ANTAGONISTS
  申请人：Heptares Therapeutics Limited

  公开号：US20170247369A1

  公开（公告）日：2017-08-31

  This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where R 1 -R 5 , X 1 , X 2 and p are as defined herein.
• US9266857B2
  申请人：——

  公开号：US9266857B2

  公开（公告）日：2016-02-23
• US9669013B2
  申请人：——

  公开号：US9669013B2

  公开（公告）日：2017-06-06